U.K.-based Exscientia, a leading drug discovery firm, has successfully advanced six molecules created with the help of generative AI into Phase 1 clinical trials. CEO and founder Andrew Hopkins envisions a future where AI plays a vital role in the design of all new therapies.
How Exscientia Reduces Drug Discovery Time With Gen AI
U.K.-based Exscientia, a leading drug discovery firm, has successfully advanced six molecules created with the help of generative AI into Phase 1 clinical trials. CEO and founder Andrew Hopkins envisions a future where AI plays a vital role in the design of all new therapies.
Niura's EEG-implemented earbuds scan your brain health and recommend music to your mood
Airbus A380 Comeback Continues As Lufthansa Announces New Business Class, Service
Lachlan Murdoch’s On-Again, Off-Again Relationship With the Family Business
Summit aims to empower youth leaders in Detroit, connect them to business community
